Agilent Technologies Inc. (NYSE: A) has received two 2023 Scientists’ Choice Awards; Best New Drug Discovery & Development Product of 2022, and Drug Discovery & Development Webinar of the Year. Announced at the SLAS2023 International Conference & Exhibition on February 27th, 2023, the Scientists’ Choice Awards recognize the world’s most innovative and effective analytical science technologies and communications.

The Drug Discovery & Development Product of 2022 was awarded to the Agilent Seahorse XF Pro Analyzer. This instrument uses label-free sensors to measure cellular respiration, glycolysis, and ATP production, which are critical to energy metabolism - the process that maintains life in all cells. Launched in February 2022, the XF Pro Analyzer incorporates improved hardware, software, and workflow features that greatly enhance performance and customer experience, particularly within pharma and biopharma therapeutic development, and toxicity programs.

“We are passionate about developing customer-focused, industry-leading technologies and as such are thrilled to win this award for our XF Pro Analyzer,” said Richard Fernandes, associate vice president and general manager of Agilent’s Seahorse business. “The fact that we won because scientists around the world voted, is the highest accolade we could hope for.”

The Drug Discovery & Development Webinar of the Year award was presented to Agilent for the ‘Bispecific-antibody-armed, metabolically enhanced headless CAR T cells: Safe and effective serial killers of solid tumors’ webinar presented by Dr. Archana Thakur, Associate Professor of Medicine, Director of Human Cellular Therapeutics cGMP Core, University of Virginia, School of Medicine. This webinar included the use of Agilent Seahorse XF technology, Agilent xCELLigence Real Time Cell Analyzer (RTCA), and the Agilent NovoCyte Flow Cytometer.

“The work that Dr Thakur and her team are doing on metabolically enhanced headless CAR T (hCAR T) cells is revolutionary. I am so pleased to see their work getting recognized through this award,” said Xiaobo Wang, general manager of Flow Cytometry and Real Time Cell Analysis at Agilent. “This new perspective of immune cell killing, fitness and persistence on CAR T therapy is just the beginning, we are excited to see where this research leads.”

Agilent’s Cell Analysis Division consists of innovative technologies in cell imaging, real-time cell analysis, flow cytometry, and more - all with the goal of rewriting the rules in the race against disease. Agilent is on a mission to help labs accelerate discoveries through the development of solutions that advance research and testing, and ultimately improve the quality of life.